A Study of Sotorasib in People With Non-Small Cell Lung Cancer

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)

Trial Details

NCT ID
NCT06582771
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sotorasib
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Written informed consent
  • Biopsy-proven metastatic or recurrent non-small cell lung cancer
  • KRAS G12C mutation on prior tumor biopsy or cell-free DNA (cfDNA) testing
  • No prior therapy in the advanced setting

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →